AML
Filters
All Videos
Insights from 2025 Tandem Annual Meeting
Tandem 2025 Insights: Management of Steroid Refractory Acute GVHD
FEATURING
David Jacobsohn
- 2 views
- March 10, 2025
Total Health
Advances in AML in 2025: Focus on Targeted Therapies
FEATURING
Naval Daver
- 1 view
- March 10, 2025
Total Health
Advances in Leukemia: Targeted Therapies and Immunotherapy
FEATURING
Jorge Cortés
- 2 views
- March 10, 2025
Moffitt Cancer Center
Debate: Should MRD Status be Used to Alter Treatment Decisions in High-Risk MDS & AML? No
FEATURING
Nelli Bejanyan
- 1 view
- March 6, 2025
Moffitt Cancer Center
Revumenib for KMT2Ar R/R Acute Leukemia - AUGMENT-101 Trial: Impact on Treatment Landscape
FEATURING
Andrew Kuykendall
- 1 view
- March 6, 2025
Moffitt Cancer Center
Progressive Paradigm Shift in the Treatment of Older Patients With AML
FEATURING
Rory Shallis
- 28 views
- February 28, 2025
Cleveland Clinic Taussig Cancer Institute
Understanding the AML Disease State: Key Challenges and Advances
FEATURING
Moaath Mustafa Ali
- 91 views
- February 28, 2025
- 1
University of Colorado Division of Hematology
ASH 2025 Review: FLT3 Inhibitors in AML - Updates and Comparative Insights
FEATURING
Mathew Angelos
- 61 views
- February 28, 2025
- 1
University of Colorado Division of Hematology
ASH 2025 Review: Updates in Venetoclax-Based & Cladribine-Based Therapies for AML
FEATURING
Mathew Angelos
- 46 views
- February 28, 2025
University of Colorado Division of Hematology
ASH 2025 Review: Menin Inhibitors, Immunotherapies, and Future Directions in AML
FEATURING
Mathew Angelos
- 31 views
- February 28, 2025
Insights from 2025 Tandem Annual Meeting
Tandem 2025 Insights: Allogeneic HCT for 1L TP53-Mutated MDS/AML: Time to Be Selective
FEATURING
Melham Solh
- 9 views
- February 27, 2025
OncoPharm
Revumenib for KMT2A+ R/R Acute Leukemias - Drug Overview and Clinical Pearls
FEATURING
John Bossaer
- 18 views
- February 14, 2025
Tisch Cancer Institute at Mount Sinai
Leukemia Tumor Board: Novel Treatment Strategies in FLT3-Mutated AML
FEATURING
Irina Krykbaeva
- 9 views
- February 11, 2025
Tisch Cancer Institute at Mount Sinai
Leukemia Tumor Board: Evolving Treatment Indications for HMA/Ven in Newly Diagnosed AML
FEATURING
Irina Krykbaeva
- 9 views
- February 11, 2025
Tisch Cancer Institute at Mount Sinai
Leukemia Tumor Board: Use of Gemtuzumab Ozogamicin in Treatment of NPM1+ AML
FEATURING
Noah Osei
- 9 views
- February 10, 2025
- 1
Shyam Patel
TP53-Mutant AML: Disease Biology, Targeted Therapies, and HSCT Insights
- 47 views
- February 10, 2025
Shyam Patel
Clonal Hematopoiesis: CHIP & CCUS Definition and Clinical Implications
- 41 views
- February 6, 2025
Tisch Cancer Institute at Mount Sinai
Leukemia Tumor Board: Pt With PMH of mTNBC Diagnosed With t-AML With Monocytic Differentiation
FEATURING
Dahniel Sastow
- 5 views
- February 6, 2025
Tisch Cancer Institute at Mount Sinai
Leukemia Tumor Board: FLT3-ITD+, NPM1+, IDH2+, Normal Karyotype AML
FEATURING
Dahniel Sastow
- 10 views
- February 6, 2025
- 1
Tisch Cancer Institute at Mount Sinai
Leukemia Tumor Board: FLT3-Mutated APL
FEATURING
Dahniel Sastow
- 13 views
- February 6, 2025
Tisch Cancer Institute at Mount Sinai
Leukemia Tumor Board: Clonal Evolution - Progression From Aplastic Anemia to MDS Then AML
FEATURING
Max Dougherty
- 14 views
- February 6, 2025
GRACE
HSCT & Cell Therapy 101: Overview of Types, Processes, Supportive Care, and Toxicities
FEATURING
Muhammad Salman Faisal
- 20 views
- February 6, 2025
Louisville Hematology Highlights
AML: Understanding Risk Stratification and Treatment Approach
FEATURING
Curtis Lachowiez
- 27 views
- January 31, 2025
- 1
Elisabetta Xue
Identifying Steroid-Refractory or Steroid-Dependent cGVHD and the Role of Ruxolitinib
- 49 views
- January 30, 2025
GRACE
Common Toxicities Associated With Allogeneic HSCT
FEATURING
Muhammad Salman Faisal
- 11 views
- January 30, 2025
Louisville Hematology Highlights
Advancements in AML Management in 2024
FEATURING
Curtis Lachowiez
- 201 views
- January 28, 2025
- 2
Moffitt Cancer Center
Cellular Therapies for Myeloid Malignancies
FEATURING
David Sallman
- 134 views
- January 28, 2025
- 1
Roswell Park Comprehensive Cancer Center
Steroid-Refractory GVHD Updates
FEATURING
Shernan Holtan
- 192 views
- January 24, 2025
City of Hope
Acute GVHD: Demographics, Diagnosis, Pathophysiology, and Advancements in Treatment With Corticosteroids & JAK Inhibitors
FEATURING
Amandeep Salhotra
- 97 views
- January 22, 2025
- 1
ecancer
ASH 2024 Insights: Survival and Outcomes in Older, Untreated AML Pts With NPM1 Mutations or KMT2A Rearrangements
FEATURING
Ashley Yocum
- 10 views
- January 21, 2025
Jad Othman
[private - duplicate] Real-World Outcomes With Venetoclax & Azacitidine in AML Patients
- 21 views
- January 16, 2025
Jad Othman
Real-World Outcomes With Venetoclax and Azacitidine in AML Patients
- 99 views
- January 15, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Menin Inhibitors in AML - FDA Approval and Highlights From ASH
FEATURING
Joshua Zeidner
- 433 views
- December 30, 2024
- 5
Giuseppe Francesco Milone
The Evolving Landscape of cGVHD Treatment Options
- 44 views
- December 27, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in AML, MDS, and ALL
FEATURING
Talha Badar
- 1,216 views
- December 24, 2024
- 6
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Transplant Options and Outcomes for TP53 Myeloid Disease
FEATURING
Hugo F. Fernandez
- 251 views
- December 23, 2024
- 1
University of Illinois Cancer Center
Latest Advancements in Targeted Therapy in AML
FEATURING
Noah Birch
- 15 views
- December 20, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ziftomenib + Ven/Aza in R/R NPM1mut or KMT2A-r AML - Interim KOMET-007 Results
FEATURING
Amir Fathi
- 73 views
- December 16, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Venetoclax + Aza for 1L Younger AML Pts Independent of Fitness for Intensive Therapy
FEATURING
Justin Watts
- 342 views
- December 16, 2024
- 5
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Clinical Study of Oral Azacitidine and Venetoclax in Newly Diagnosed and R/R AML
FEATURING
Maria Amaya
- 125 views
- December 13, 2024
- 1
Oncology Data Advisor
Navigating Hereditary Hematologic Malignancy Genetics
FEATURING
Sarah Bannon,
Hiam Abdel-Salam
- 31 views
- November 27, 2024
16th International Congress on Myeloproliferative Neoplasms
PV and Its Relationship to Acute Leukemia
FEATURING
Jerry L. Spivak
- 93 views
- November 26, 2024
- 2
Weill Cornell Medicine Oncology & Hematology
Secondary AML: Best Therapy Options
FEATURING
Pinkal Desai
- 138 views
- November 21, 2024
Noah Merin
Axatilimab in cGVHD: Mechanism of Action and Comparison With Current Therapeutic Agents
- 123 views
- November 10, 2024
UChicago Medicine
Current Management of Accelerated/Blast-Phase MPNs
FEATURING
Anand Patel
- 86 views
- October 25, 2024
- 1
Marina Konopleva
Considering Venetoclax in AML and ALL - Which Patients and Why
- 69 views
- October 23, 2024
- 2
Cleveland Clinic Taussig Cancer Institute
Updates in APL: Current SoC and Future Directions
FEATURING
Ben Tomlinson
- 47 views
- October 22, 2024
Yale Cancer Center
Myeloid Malignancies: Hot Topics in 2024
FEATURING
Nikolai Podoltsev
- 378 views
- October 21, 2024
Najla El-Jurdi
CSF1R's Role in Modulating Inflammation & Fibrosis in cGVHD
- 44 views
- October 16, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Case-Based Discussion of MRD in AML
FEATURING
Mehreen Ali Khan
- 25 views
- October 15, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Practical Management of AML and MDS in the Elderly
FEATURING
Turgay Ulaş
- 21 views
- October 15, 2024
Brittany Ragon
Targeting cGVHD: Mechanism of Action of Axatilimab Compared to Other Available Agents
- 30 views
- October 14, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Targeted Therapies in AML With a Focus on FLT3 Inhibitors
FEATURING
Naval Daver
- 42 views
- October 8, 2024
Masonic Cancer Center, University of Minnesota
The Genetic Epidemiology and Early-Life Origins of Childhood Leukemia
FEATURING
Adam de Smith
- 10 views
- October 8, 2024
Masonic Cancer Center, University of Minnesota
Blood Cancers Basics
FEATURING
Zohar Sachs
- 39 views
- October 7, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: IDH Mutated AML - Diagnostic and Treatment Paradigm
FEATURING
Teresa Macarulla Mercade
- 59 views
- September 30, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
AML Case Discussion: FLT3-ITD+ High-Risk Disease
FEATURING
Fehmi Hindilerden
- 29 views
- September 27, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Management of ATRA-Related Pneumatosis Cystoides Intestinalis in a Patient with APL
FEATURING
Emel Isleyen Kaya
- 6 views
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights in Heme Malignancies
FEATURING
Maria Gomes da Silva
- 584 views
- September 23, 2024
- 2
Houston Methodist
Current Treatment Landscape in Myeloid Malignancies
FEATURING
Shilpan Shah
- 63 views
- September 11, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Management of R/R AML: Treatment Options and Case Insights
FEATURING
Valentina Bonuomo
- 47 views
- September 11, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in AML: 7+3 Is No Longer the Standard of Care
FEATURING
Tapan Kadia
- 1,111 views
- September 11, 2024
- 13
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Practical Approach to MRD Monitoring in AML: Assessing Treatment Efficacy and Relapse Risk
FEATURING
Tapan Kadia
- 112 views
- September 11, 2024
Daniel Wolff
The Role of Axatilimab in Targeting CSF1R for Inflammation and Fibrosis in cGVHD – Recently FDA Approved
- 173 views
- September 6, 2024
- 1
UChicago Medicine Annual Practice Updates in Hematology and Oncology
UChicago Medicine Best of ASCO® 2024: CML, AML, ALL
FEATURING
Mariam Nawas
- 45 views
- September 3, 2024
MyCancerHaven
Hematopoetic Stem Cell Transplant: How I Decide
FEATURING
Ravi Vij,
Sanghee Hong
- 100 views
- August 30, 2024
- 2
MyCancerHaven
Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPDCN
FEATURING
Ravi Vij,
Guru Murthy
- 698 views
- August 30, 2024
- 3
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Management of AML in Older Patients
FEATURING
Farhad Ravandi
- 223 views
- August 29, 2024
University of Miami Sylvester Comprehensive Cancer Center
Current and Emerging Treatment Approaches for Patients With AML or MDS
FEATURING
Sangeetha Venugopal
- 151 views
- August 26, 2024
Jesse Hirner
BPDCN: A Dermatologist's Perspective on Differential Diagnosis
- 1,678 views
- August 16, 2024
- 10
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in AML: 3+7 is the SOC Induction Therapy for AML
FEATURING
Ant Uzay
- 66 views
- August 15, 2024
- 1
Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course
AML: Diagnosis, Trends, and Approaches
FEATURING
Mary-Beth Percival
- 186 views
- August 14, 2024
Robert Zeiser
CSF1R's Role in Modulating Inflammation and Fibrosis in cGVHD
- 61 views
- August 13, 2024
- 1
Giuseppe Francesco Milone
Steroid-Refractory GvHD Management: When to Switch From Steroids
- 96 views
- August 1, 2024
ecancer
Post-Transplant Cyclophosphamide Based GVHD Prophylaxis in Patients Undergoing MMUD HCT
FEATURING
Monzr Al Malki,
Steven Devine
- 48 views
- July 24, 2024
ecancer
EHA 2024 Insights: APOLLO Trial Summary - ATRA + ATO vs. Standard ATRA + Chemo in High-Risk APL
FEATURING
Uwe Platzbecker
- 95 views
- July 24, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Real-World Data From R/R BPDCN Treated With Tagraxofusp
FEATURING
Emanuele Angelucci
- 230 views
- July 23, 2024
- 1
Vanderbilt University Medical Center (VUMC)
Age Limits in Stem Cell Transplants and Cell Therapy
FEATURING
Reena Jayani
- 66 views
- July 22, 2024
Vanderbilt University Medical Center (VUMC)
Pre-Transplant Management of High-Risk AML
FEATURING
Kateryna Fedorov
- 103 views
- July 18, 2024
- 2
Vanderbilt University Medical Center (VUMC)
Prevention and Management of Post-SCT Relapse in Acute Leukemias
FEATURING
Andrew Jallouk
- 283 views
- July 18, 2024
- 6
Insights from 2024 EHA Annual Meeting
AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024
FEATURING
Talha Badar
- 821 views
- July 16, 2024
- 4
SOHO Brazil 2024
Where I Use Azacitidine and Venetoclax in AML: Present and Future
FEATURING
Jeffrey Lancet
- 528 views
- July 11, 2024
- 4
SOHO Brazil 2024
Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde
FEATURING
Jeffrey Lancet
- 593 views
- July 11, 2024
- 2
SOHO Brazil 2024
The Gold Standard in the Use of FLT3 and IDH Inhibitors in AML
FEATURING
Jeffrey Lancet
- 142 views
- July 11, 2024
Total Health
Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL, MM, and CLL
FEATURING
Marcello Maria Rotta
- 351 views
- July 8, 2024
Icahn School of Medicine at Mount Sinai
Boosting MHC:TCR Interactions in AML
FEATURING
Iannis Aifantis
- 35 views
- July 2, 2024
Icahn School of Medicine at Mount Sinai
Therapeutic Targeting of RNA Splicing Factor Mutant Leukemias
FEATURING
Omar Abdel-Wahab
- 62 views
- July 2, 2024
Yale Cancer Center
The Role of Hypomethylating Agent Maintenance in AML
FEATURING
Rory Shallis
- 121 views
- July 1, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: FLAG-GO vs. FLAG-IDA in Untreated Core Binding Factor AML
FEATURING
Gautam Borthakur
- 151 views
- July 1, 2024
- 2
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Final 5-Year Results of Olutasidenib for Mutated IDH1 AML
FEATURING
Jorge Cortés
- 29 views
- June 28, 2024
- 1
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: AML Highlights - Focus on Menin Inhibitors
FEATURING
Joshua Zeidner
- 69 views
- June 26, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: FLAG-IDA + Venetoclax in Newly Diagnosed or R/R AML
FEATURING
Wei-Ying Jen
- 253 views
- June 26, 2024
- 2
2024 ASCO® Annual Meeting Insights Hub
Understanding New Strategies to Prevent and Manage Chronic GVHD
FEATURING
Betty Hamilton
- 112 views
- June 16, 2024
- 1
Icahn School of Medicine at Mount Sinai
Integrating Targeted Therapies in AML
FEATURING
Hagop Kantarjian
- 429 views
- May 31, 2024
- 3
Icahn School of Medicine at Mount Sinai
Navigating aGVHD Treatment: Integrating Recent Updates in Clinical Management
FEATURING
James Ferrara
- 84 views
- May 31, 2024
Icahn School of Medicine at Mount Sinai
BPDCN: Current and Future Directions
FEATURING
Naveen Pemmaraju
- 524 views
- May 31, 2024
- 2
Rush University Medical Center
[duplicate] Is Post-HSCT Maintenance the SOC for AML?
FEATURING
Mark Levis
- May 29, 2024
Rush University Medical Center
What is New in AML: Risk Classification, Germline Mutations, and Targeted Therapies
FEATURING
Ehab Atallah
- 321 views
- May 29, 2024
- 2
Rush University Medical Center
Is Post-HSCT Maintenance the SOC for AML?
FEATURING
Mark Levis
- 346 views
- May 29, 2024
- 4
Rush University Medical Center
Allo-HSCT Conditioning Regimens: Current Status and Future Directions
FEATURING
Claudio Brunstein
- 287 views
- May 24, 2024
Rush University Medical Center
Selection and Sequencing of Chronic GVHD Therapy
FEATURING
Satyajit Kosuri
- 301 views
- May 24, 2024
- 1
Rush University Medical Center
Management of Viral Infections Post-Transplant: CMV, EBV, and HHV-6
FEATURING
Eric Bhaimia
- 355 views
- May 24, 2024
MyCancerHaven
Experts Discuss How to Approach Frontline Treatment of Unfit Patients With AML
- 116 views
- May 22, 2024
Yale Cancer Center
Yale Cancer Center Allogeneic Stem Cell Transplantation Updates
FEATURING
Lohith Bachegowda
- 89 views
- May 21, 2024
Yale Cancer Center
Summary of Promising Recent Studies in LR-MDS, HR-MDS, and R/R AML
FEATURING
Rory Shallis
- 92 views
- May 16, 2024
Yale Cancer Center
Splicing Factor Mutations in MDS: Role in Disease Biology and Potential Therapeutic Targeting
FEATURING
Stephanie Halene
- 30 views
- May 15, 2024
Tisch Cancer Institute at Mount Sinai
Tumor Board: Myeloid Sarcoma Manifesting as Small Bowel Obstruction
FEATURING
Justine Anderson
- 27 views
- May 6, 2024
- 1
Tisch Cancer Institute at Mount Sinai
Leukemia Tumor Board: 25 y/o With FLT3-TKD+ AML
FEATURING
Justine Anderson
- 88 views
- May 6, 2024
Indy Hematology Review
Current & Emerging Therapies for AML and MDS
FEATURING
Rami Komrokji
- 198 views
- May 3, 2024
- 1
Memorial Sloan Kettering Cancer Center
Key Updates in AML, MDS, & MF From ASH
FEATURING
Aaron Goldberg
- 319 views
- May 2, 2024
- 4
MyCancerHaven
Updates in Frontline Treatment of Fit Patients With AML
FEATURING
Ravi Vij,
Manuel Espinoza Gutarra
- 107 views
- April 30, 2024
Indy Hematology Review
R/R AML: Current, Emerging, and Targeted Therapies
FEATURING
Rami Komrokji
- 362 views
- April 22, 2024
- 3
Indy Hematology Review
HSCT in 2024: What Every Hematologist Needs to Know
FEATURING
Richard Childs
- 871 views
- April 18, 2024
- 5
Indy Hematology Review
Treatment of AML: Managing the Patient When Transplant Is Not an Option
FEATURING
Harry P. Erba
- 965 views
- April 17, 2024
- 7
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignancies
FEATURING
Ruemu Birhiray
- 974 views
- April 16, 2024
- 5
University of Colorado Division of Hematology
2024 Updates in AML
FEATURING
Christine McMahon
- 792 views
- April 16, 2024
- 7
MyCancerHaven
Experts Discuss the Role of Stem Cell Transplant in AML
FEATURING
Ravi Vij,
Muzaffar Qazilbash
- 117 views
- April 11, 2024
- 1
Zachariah DeFilipp
Axatilimab in Chronic GVHD: Updates From the AGAVE-201 Study
- 244 views
- March 27, 2024
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: AML
FEATURING
Farhad Ravandi
- 391 views
- March 25, 2024
- 2
UChicago Medicine
Updates in Transplantation and GVHD From Recent Meetings
FEATURING
Mariam Nawas
- 118 views
- March 25, 2024
Insights from 2023 ASH Annual Meeting
FLT3-ITD Mutated AML: PROs From the QuANTUM-First Trial of Quizartinib vs. Standard Chemo
FEATURING
Esther Oliva
- 155 views
- March 22, 2024
UChicago Medicine
AML: Current Treatment Landscape and Key Recent Updates
FEATURING
Anand Patel
- 395 views
- March 20, 2024
- 3
Scripps Health
Managing Intensive-Chemotherapy Ineligible Patients With AML
FEATURING
Courtney D. DiNardo
- 179 views
- March 20, 2024
- 2
Scripps Health
FLT3-Mutated AML: Advances in Frontline Treatment
FEATURING
Nicholas Short
- 253 views
- March 19, 2024
i3 Health
MRD Testing in Leukemias: When Negativity Is a Positive Thing
FEATURING
Noopur S. Raje
- 485 views
- March 15, 2024
- 1
Yale Cancer Center
Targeting Apoptosis in Leukemia: Lessons and Challenges
FEATURING
Marina Konopleva
- 111 views
- March 15, 2024
- 1
City of Hope
Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Targeted Strategies
FEATURING
Idoroenyi Amanam
- 221 views
- March 11, 2024
- 1
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Immunotherapies in Acute Leukemias: 2024 Update
FEATURING
Catherine Lai
- 554 views
- March 11, 2024
- 3
Moffitt Cancer Center
Using Transplant in Patients With p53 Mutant MDS or AML
FEATURING
Hany Elmariah
- 387 views
- March 7, 2024
- 5
Masterclasses in Dermatology
Masterclasses from the Wards
FEATURING
Scott Elman
- 329 views
- March 6, 2024
- 2
Moffitt Cancer Center
Optimal Use of Targeted Therapy for the Elderly or Unfit AML Patient
FEATURING
Onyee Chan
- 109 views
- March 5, 2024
Talha Badar
Challenges in the Management of TP53-Mutated AML: Potential Strategies to Improve Outcomes
- 460 views
- March 5, 2024
- 4
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Emerging Treatment Options for AML in 2024
FEATURING
Alexander Perl
- 741 views
- March 3, 2024
- 4
Louisville Hematology Highlights
New Directions in CAR-T: Targeting Novel Antigens
FEATURING
Robert Emmons
- 148 views
- February 27, 2024
- 2
Louisville Hematology Highlights
Is a Bigger Induction "Hammer" Necessarily Better in Today's Stem Cell Transplantation?
FEATURING
William Tse
- 116 views
- February 27, 2024
- 1
Louisville Hematology Highlights
The Use of Allo-HCT in the Management of AML
FEATURING
Gordon Phillips
- 31 views
- February 26, 2024
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
FEATURING
Robert Peter Gale
- 4,721 views
- February 26, 2024
- 21
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Clinical Case of BPDCN
FEATURING
Hanan Hamed
- 25 views
- February 23, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
How I Manage Febrile Neutropenia in Patients With Cancer
FEATURING
Şiran Keske
- 77 views
- February 21, 2024
- 1
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
A 50-Year Personal Perspective on the Treatment of AML
FEATURING
Charles A. Schiffer
- 168 views
- February 21, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Acute Promyelocytic Leukemia: Risk Stratification and New Treatment Modalities
FEATURING
Suar ÇAkı Kılıç
- 91 views
- February 16, 2024
- 1
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Pediatric AML: Diagnosis and Risk Stratification
FEATURING
Nihal Karadaş
- 179 views
- February 16, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
The Truth About Current Consensus Statements on Hematopoietic Cell Transplant
FEATURING
Robert Peter Gale
- 539 views
- February 15, 2024
- 2
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
State of the Art: Role of Maintenance Therapy in AML
FEATURING
Zeba Aziz
- 235 views
- February 15, 2024
Insights from 2023 ASH Annual Meeting
AML and MDS Highlights & Key Takeaways
FEATURING
Talha Badar
- 2,236 views
- January 24, 2024
- 14
MyCancerHaven
Experts Discuss the Use of Targeted Therapies in AML
FEATURING
Ravi Vij,
Eunice Wang
- 244 views
- January 23, 2024
- 1
Penn Medicine Abramson Cancer Center
Latest Advances in Managing AML in Older Adults - Choosing Therapy and Considerations for Transplant
FEATURING
Shannon McCurdy
- 83 views
- January 19, 2024
ecancer
ASH 2023 Insights: "Updates From the Beat AML Master Trial - A Precision Medicine Approach to AML"
FEATURING
Ashley Yocum
- 32 views
- January 19, 2024
ecancer
ASH 2023 Insights: "AUGMENT-101 - Revumenib Monotherapy in Pts With R/R KMT2Ar Acute Leukemia"
FEATURING
Ibrahim Aldoss
- 59 views
- January 18, 2024
- 1
Masonic Cancer Center, University of Minnesota
"Sleeping Beauty" Implicates Drivers of Leukemic Progression in Mice With Trp53R270H Mutation
FEATURING
Daniel Chang
- 43 views
- January 17, 2024
Insights from 2023 ASH Annual Meeting
The Future Paradigm of HMA + Ven or Targeted Agents in AML: Sequencing and Triplet Combinations
FEATURING
Justin Watts
- 180 views
- January 17, 2024
- 5
Insights from 2023 ASH Annual Meeting
Treatment Strategies for Hematocrit Control in PV
FEATURING
Amy Zhou
- 955 views
- January 8, 2024
- 6
Insights from 2023 ASH Annual Meeting
Chronic GVHD: Results from Agave-201 - Axatilimab at 3 Different Doses
FEATURING
Daniel Wolff
- 109 views
- December 29, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Revumenib Monotherapy in Pts With R/R KMT2Ar Acute Leukemia From the AUGMENT-101 Study"
FEATURING
Ibrahim Aldoss
- 102 views
- December 29, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "PROs From BMT CTN 1703 Study in GVHD Prophylaxis - a QoL Evaluation"
FEATURING
Shernan Holtan
- 27 views
- December 22, 2023
Insights from 2023 ASH Annual Meeting
FLT3-ITD Mutated AML: QuANTUM-First - Safety by Treatment Phase and by Age in ND Patients
FEATURING
Harry P. Erba
- 211 views
- December 22, 2023
Insights from 2023 ASH Annual Meeting
FLT3-ITD Mutated AML: Quizartinib, Venetoclax, & Decitabine Triple Combination
FEATURING
Musa Yilmaz
- 142 views
- December 15, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Results From a Ph1 Study of the All-Oral Regimen of CC-486 and Venetoclax For R/R AML"
FEATURING
Maria Amaya
- 158 views
- December 14, 2023
Insights from 2023 ASH Annual Meeting
Prevalence and Prediction of Ruxolitinib Treatment Emergent Thrombocytopenia in Myelofibrosis
FEATURING
Douglas Tremblay
- 436 views
- December 13, 2023
- 1
Talha Badar
DDX41 Mutated Germline Predisposition Syndrome-Associated Myeloid Neoplasms - What You Need to Know
- 251 views
- December 4, 2023
- 2
5th SOHO Italy Annual Conference
SOHO Italy 2023: Immune and Cellular Approaches for AML - Current and Future Directions
FEATURING
Naval Daver
- 33 views
- November 30, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: Overcoming HSP90 Inhibitor Resistance in NPM1 Mutated AML
FEATURING
Ilaria Gionfriddo
- 13 views
- November 30, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: The Role of Molecular MRD Monitoring in AML - NGS Approaches
FEATURING
Konstanze Doehner
- 24 views
- November 30, 2023
5th SOHO Italy Annual Conference
How I Treat BPDCN at MD Anderson Cancer Center
FEATURING
Naveen Pemmaraju
- 287 views
- November 30, 2023
- 1
5th SOHO Italy Annual Conference
SOHO Italy 2023: Current Role of Allogenic Stem Cell Transplantation and Maintenance in AML
FEATURING
Attilio Olivieri
- 14 views
- November 30, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: How I Manage Secondary AML
FEATURING
Francesco Lanza
- 27 views
- November 30, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: New Insights in AML
FEATURING
Mauricette Michallet
- 39 views
- November 30, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: Anti-Leukemic Aurora A Activity in NPM1-mut AML Models
FEATURING
Roberta Ranieri
- 15 views
- November 30, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: Overcoming Resistance to Venetoclax in AML - A Radical Approach
FEATURING
Vittoria Raimondi
- 130 views
- November 30, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: How I Treat AML at MD Anderson Cancer Center
FEATURING
Hagop Kantarjian
- 608 views
- November 28, 2023
- 8
Nebraska Oncology Society
Survivorship After Transplant and CAR-T for Hematologic Malignancies
FEATURING
Nausheen Ahmed
- 112 views
- November 27, 2023
5th SOHO Italy Annual Conference
A New Innovative Targeted Therapy for Patients With BPDCN
FEATURING
Giovanni Martinelli
- 560 views
- November 27, 2023
- 1
5th SOHO Italy Annual Conference
Characterization and Diagnosis of BPDCN
FEATURING
Sara Fraticelli
- 640 views
- November 27, 2023
- 2
5th SOHO Italy Annual Conference
Treatment and Management of BPDCN: Clinical Data and Long-Term Outcomes
FEATURING
Giovanni Marconi
- 330 views
- November 27, 2023
5th SOHO Italy Annual Conference
Case Presentation - Treatment and Management of BPDCN
FEATURING
Marianna Rossi
- 50 views
- November 27, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: Non-Intensive Treatment of Elderly/Unfit Pts With AML - Beyond Venetoclax + HMAs
FEATURING
Tapan Kadia
- 44 views
- November 27, 2023
- 1
5th SOHO Italy Annual Conference
SOHO Italy 2023: How I Manage FLT3 Mutated AML - Moving Towards Cure
FEATURING
Giovanni Martinelli
- 24 views
- November 27, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: How I Manage IDH-Mutated AML at MD Anderson Cancer Center
FEATURING
Courtney D. DiNardo
- 74 views
- November 27, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: The Pathogenesis of Acute Leukemias - Approaches and Molecular Insights
FEATURING
Ilaria Iacobucci
- 44 views
- November 27, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: WHO 2022 Classification of MPNs - Transitioning From the Optical Into the Molecular Era
FEATURING
Hanan Hamed
- 25 views
- November 27, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: Is The Future of AML All Oral Therapy?
FEATURING
Farhad Ravandi
- 77 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: New Strategies in Induction of Transplant-Eligible AML
FEATURING
Giovanni Marconi
- 20 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: TP53 in Myeloid Leukemias - Targeting the Guardian of the Genome
FEATURING
Micheal Andreeff
- 51 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: Role of Immune Checkpoint Inhibitors in AML
FEATURING
Amer Zeidan
- 23 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: Targeted Diagnosis & Therapy of NPM1-Mutated AML
FEATURING
Brunangelo Falini
- 48 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: NPM1-Mutated AML - From Bench to Bedside
FEATURING
Lorenzo Brunetii
- 47 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: A New Conditioning Regimen Pre-Allogeneic Stem Cell Transplantation
FEATURING
Jean El-Cheikh
- 88 views
- November 25, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Emerging BCL2 Inhibitors
FEATURING
Mary Ann Anderson
- 139 views
- November 21, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Next Questions: AML
FEATURING
Farhad Ravandi
- 124 views
- October 25, 2023
- 1
University of Colorado Division of Hematology
Oncological Emergencies in AML
FEATURING
Glen Peterson
- 165 views
- October 24, 2023
- 1
University of Colorado Division of Hematology
Current Management of APL and AML
FEATURING
Keri Halsema
- 135 views
- October 24, 2023
University of Colorado Division of Hematology
Management of Common Emergencies in Blood Cancers
FEATURING
Glen Peterson
- 191 views
- October 24, 2023
University of Colorado Division of Hematology
Overview of Physical Exams, Labs and Diagnostic Testing for Blood Cancer Patients
FEATURING
Meredith Beaton
- 32 views
- October 24, 2023
UNC Lineberger Comprehensive Cancer Center
UNC Updates on Caring for Older Adults With Acute Leukemia in 2023
FEATURING
Daniel Richardson
- 84 views
- October 23, 2023
Yale Cancer Center
Immune Checkpoint Inhibition and Novel Therapies for Myelodysplastic Syndromes/Neoplasms
FEATURING
Amer Zeidan
- 174 views
- October 23, 2023
ecancer
Epitope Editing Enables Targeted Immunotherapy of AML
FEATURING
Gabriele Casirati
- 22 views
- October 23, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: What Is New in the WHO Classification of AML?
FEATURING
Sanam Loghavi
- 62 views
- October 19, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: What Is New in the ICC Classification of AML?
FEATURING
Robert Paul Hasserjian
- 43 views
- October 19, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: How Do We Reconcile These AML Classifications in Clinical Management and Research?
FEATURING
Andrew Wei
- 26 views
- October 19, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 DEBATE: Prior Therapy Not Needed for Transplanting Patients With R/R AML
FEATURING
Johannes Schetelig
- 21 views
- October 19, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Familial Predisposition to AML: Prevalence & Implications for Management
FEATURING
Lucy Godley
- 35 views
- October 19, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Impact of Consolidation Chemo Intensity Before Allogeneic HSCT in Elderly Patients With AML
FEATURING
Yosr Hicheri
- 19 views
- October 19, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 DEBATE: Patients With AML and Active Disease Should Be Transplanted
FEATURING
Hugo F. Fernandez
- 111 views
- October 19, 2023
- 4
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: What Is the Future of Menin Inhibitors in AML?
FEATURING
Ghayas Issa
- 179 views
- October 18, 2023
- 1
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Update on CHIP and CCUS
FEATURING
Lachelle Weeks
- 254 views
- October 18, 2023
- 1
University of Colorado Division of Hematology
Venetoclax and Transplant in AML: Oh, the Places You’ll Go!
FEATURING
Jonathan Gutman
- 111 views
- October 17, 2023
University of Colorado Division of Hematology
Novel Therapies in AML and MDS
FEATURING
Daniel Pollyea
- 528 views
- October 17, 2023
- 2
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Triplet Regimens in AML: Beyond Azacitidine + Venetoclax
FEATURING
Courtney D. DiNardo
- 389 views
- October 16, 2023
- 1
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Is AML With Monocytic Features a Separate Entity?
FEATURING
Daniel Pollyea
- 141 views
- October 6, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: What Is the Role of Quizartinib in the Current Landscape of Initial AML Therapy?
FEATURING
Harry P. Erba
- 69 views
- October 5, 2023